Diabetic patients? Human stem cells to produce insulin-producing cells for treatment
Diabetic patients? Human stem cells to produce insulin-producing cells for treatment
According To Reports, Over 415 Million People Have Been Diagnosed With Diabetes Globally. Diabetes Patients Lack The Ability To Produce Sufficient Amounts Of Insulin, Which Regulates The Blood Sugar In The Body. This Can Result In A Number Of Complications And In Many Cases Be Potentially Fatal.
News Nation Bureau | Edited By : Neha Singh | Updated on: 08 Nov 2017, 02:47:48 PM
New Delhi:
Good News! In the new study, published in the Journal Nature Cell Biology, shows that Human stem cells can now be used to produce insulin-producing cells that can be transplanted into diabetes patients in future.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
Erytech Pharma S.A.April 20, 2021 GMT
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH invited by FDA to request a pre-BLA meeting
First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial
Lyon (France) and Cambridge, MA (U.S.), April 20, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration (US FDA) for its lead product candidate eryaspase in patients with acute ly
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Onegevity and EmbodyBio Announce Collaboration to Explore Brain Health
April 19, 2021 GMT
NEW YORK, April 19, 2021 /PRNewswire/ Onegevity (a division of Thorne HealthTech), a health intelligence company with a proprietary, multi-omic platform that leverages artificial intelligence (AI) and machine learning to map, integrate, and understand the billions of dynamic and biological features that showcase the state of an individual’s health, and EmbodyBio, a startup company at the forefront of ‘digital twin’ technology, today announced a new collaboration aimed at creating next-generation capabilities to advance brain health.